Conform to the international trend of Chinese medicine medicine network

July 17, 2010 09:59:19 China Pharmaceutical Network

      In recent years, the development of Chinese medicine has been raised to the national height. "National Innovation-Driven Development Strategy Outline", "Healthy China 2030" Outline Plan and "Outline of the Strategic Plan for the Development of Traditional Chinese Medicine (2016-2030)", all of which will focus on the development of Chinese medicine science and technology innovation, Scientific and technological innovation made a clear request.

      Recently issued the "thirteen five" special scientific and technological innovation in traditional Chinese medicine planning, "proposed to accelerate the transmission and innovation of Chinese medicine to achieve the revitalization of the cause of the development of Chinese medicine, and put forward" improve the international standards of Chinese medicine, the formation of not less than 50 Pharmacopoeia standards and 100 industry standards, to achieve 20 to 30 varieties of drug registration and 5 to 10 varieties of proprietary Chinese medicines in Europe and the United States drug registration; to strengthen international cooperation in Chinese medicine research "and other strategic objectives for the Chinese medicine products International To create a good time, geography, and the good times.

      Significant increase in industrial output

      With the innovation of science and technology, the development of modern Chinese medicine industry has been booming. The total industrial output value of traditional Chinese medicine industry has increased from RMB 23.4 billion in 1996 to 786.7 billion yuan in 2015, accounting for 1/10 of the total output value of pharmaceutical industry Pharmaceutical products and services to speed up the world.

      According to WHO statistics, Chinese medicine has been in Australia, Canada, Austria, Singapore, Vietnam and other 29 countries and regions in the form of government legislation to be recognized; 18 countries and regions will be included in the medical insurance; Chinese medicine in Russia, Singapore, Cuba , Vietnam and other countries registered to Shenwei, Lanzhou Buddha, to Austrian Group, represented by a group of Chinese medicine enterprises take the initiative to apply for international high-end certification. At present, China has four kinds of Chinese medicine has been approved by the FDA to carry out Ⅲ clinical research, a number of Chinese herbal medicine varieties have been included in the "US Pharmacopoeia" and "EU Pharmacopoeia."

      Drug companies cloth network global

     Conform to the international trend of Chinese medicine, Chinese medicine products like mushroomed rapid development. In March 2012, the Austrian Olympic Group's "Di Austrian Heart Kang Capsule" was approved by the Dutch Pharmacopoeia Board of Directors for permission to go public. In 2016, Tasly's Modern Chinese Medicine Salvia Capsule was approved by the European Union for Plant Drugs, and the success of the drug has entered the European market.

     At the same time, some of the internationalization of Chinese medicine enterprises began to invest in mergers and acquisitions, etc. established in the global marketing network. 2013 Tianshi force to invest 1.82 million euros acquisition of the Netherlands Haidebao Management Co., Ltd. under the Netherlands China Medical Center Co., Ltd., the establishment of the Netherlands Shenzhou Tasly Pharmaceutical Group Co., Ltd. in September 2016 to Ling Pharmaceutical subsidiary to Ling Health City Technology Co., Ltd. And strategic cooperation with Israel HealthWatch, invested 15 million US dollars to become its largest shareholder.